Breaking Research News from sources other than Breastcancer.org
Comments
-
Blue light exposure at night linked to higher risk of developing breast and prostate cancer
A study... reports a link between exposure to blue light at night and higher risk of developing breast and prostate cancer. Blue light is a range of the visible light spectrum emitted by most white LEDs and many tablet and phone screens. The results have been published in Environmental Health Perspectives.
https://www.news-medical.net/news/20180425/Blue-li...
-
Elevated Serum RAS p21 Predicts Worse Outcomes in Metastatic Breast Cancer
TAKE-HOME MESSAGE
- In this multicenter, open-label study, blood samples were obtained from 251 patients with metastatic breast cancer prior to treatment with first- or later-line therapy to determine the clinical relevance of RAS p21 levels. Of these patients, 12% had levels above the cutoff level of 452 pg/mL. RAS p21 levels did not correlate with clinical–pathological parameters but was significantly associated with shorter progression-free and overall survival in patients with elevated vs non-elevated levels. On multivariate analysis, significant predictors of shorter overall survival were RAS p21, higher grade, higher line of therapy, and presence of ≥5 CTCs per 7.5 mL blood.
- These results demonstrate worse clinical outcomes in patients with elevated levels of circulating RAS p21, suggesting that they may benefit from therapies targeting the RAS pathway.
https://www.practiceupdate.com/c/68102/67/13/?elsc...
{I had not heard of this testing before. Has anyone had it? Can you offer insight? Thx.}
-
Peripheral Neuropathy Is More Severe With Paclitaxel Than With Docetaxel in Patients With Breast Cancer
This finding from a secondary data analysis was reported at the presented at the Oncology Nursing Society 43rd Annual Congress, from May 17 – 20 {2018}.
https://www.practiceupdate.com/c/67597/67/13/?elsc...
{Neuropathy is a significant side effect for cancer patients so I was interested to see this study. (I had Docetaxel and no or inconsequential neuropathy.)}
-
https://www.sciencedaily.com/releases/2018/05/180524141715.htm
Some basic Research on antibiotics, the gut microbiome and liver tumor growth.
-
Senate to take up Trump's call to lower drug prices in June
https://www.washingtonexaminer.com/policy/healthca...
-
New Push to Topple Affordable Care Act Looms
Republicans want to give states more control over health policy as midterm elections approach
https://www.wsj.com/articles/new-push-to-topple-af...
Conservative coalition crafts plan to repeal ACA Republicans and advocacy groups led by former US Sen. Rick Santorum plan to release a proposal aimed at repealing the Affordable Care Act before the midterm elections in November. The coalition of conservative groups has spent eight months crafting a proposal that would give states more control over health care, but Republicans are mixed on whether it is advantageous to bring up the issue again.
{ 1) Not trying to start a political feud, just want to keep people apprised of health coverage issues. 2) This article appeared in the WSJ. The WSJ uses a subscription model so you may have to access this info at a library, etc., if you do not subscribe. Or watch the press. I am sure other publications will be reporting on the topic.}
-
Congress Passes "Right to Try" Bill
House lawmakers passed a 'right-to-try' bill last week, clearing the path for the president to sign it.
http://nursing.advanceweb.com/congress-passes-righ...
-
Three breast cancer abstracts to watch at ASCO Annual Meeting
-
Came via email this morning:
Community Oncology Alliance Files Lawsuit Against Federal Government to Stop Unconstitutional Cut to Cancer Drug Reimbursement Application of 2% Sequester Cut to Medicare Part B Drug Reimbursement is Unconstitutional and Illegal; Costing Seniors and Taxpayers Billions The Community Oncology Alliance (COA) has filed a lawsuit in the U.S. District Court for the District of Columbia to stop the United States Department of Health and Human Services (HHS) and the White House Office of Management and Budget (OMB) from applying the Medicare sequester cut to reimbursement for Part B drugs. In the lawsuit, COA, which represents more than 5,000 independent, community-based oncologists, shows the sequester cut has harmed patients, decimated the nation's independent community cancer care system, and cost seniors and taxpayers billions in unnecessary health care spending.
Sequestration is an automatic cut to Federal government spending triggered because Congress was unable to negotiate a balanced budget in 2011. The blunt budget cutting gimmick has been extended multiple times, with the current sequester scheduled to continue through 2027. Beginning in 2013, the Centers for Medicare & Medicaid Services (CMS) began to apply a 2% budget sequester cut to all Medicare Part B reimbursement, including for drugs. The lawsuit seeks injunctive relief to specifically stop CMS from applying the sequester cut to Part B drug reimbursement.
The application of the sequester cut to cancer drug payment set up the nation's cancer care system for the closure or consolidation of independent community oncology practices, where the majority of Americans with cancer are treated. This has created access problems for patients as cancer care moves into the much more expensive hospital system, driving up costs for seniors with limited mobility and fixed incomes, as well as all taxpayers who fund Medicare.
As the 2018 Community Oncology Practice Impact Report notes, since the sequester started in 2013, approximately 135 independent community cancer clinics – many comprised of multiple locations – have been forced to close their doors, and approximately 190 clinics have been acquired by hospitals. Research has found that the consolidation of community cancer practices into hospitals cost Medicare and taxpayers an extra $2 billion in 2014 alone. In addition, Medicare beneficiaries responsible for the 20% coinsurance saw their bills rise by $500 million in that same year.
The lawsuit notes that application of the sequester cut to Part B drug reimbursement is both illegal and unconstitutional. This is because Part B drug reimbursement was set by Congress at average sales price (ASP) plus 6% in law in the Medicare Modernization Act of 2003. By applying the sequester cut to Part B drug reimbursement, the Administration has bypassed Congress and the law by lowering Part B drug payments to ASP plus 4.3%. As such, HHS and OMB are violating the separation-of-powers doctrine of the Constitution. Simply put, the Executive Branch cannot amend legislation passed by Congress under the guise of executing the laws.
In conjunction with the complaint, COA also sent a letter to HHS Secretary Alex Azarexplaining why legal action was a last resort, providing preliminary input on why proposed Medicare Part B changes in the President's blueprint on drug prices will be harmful to cancer patients, and outlining some of COA's solutions to increasing cancer drug prices, as well as reiterating community oncology's desire to work together with the Trump Administration.
"We are filing this lawsuit on behalf of the millions of Americans who face cancer and should be able to get high-quality, affordable, cancer care close to home. The sequester has been one of the biggest reasons why they can't do that, and it is time for this to stop," said Jeff Vacirca, MD, FACP, president of COA and CEO of NY Cancer Specialists. "I see the impact of the sequester cut to Part B drug reimbursement to patients and practices on a daily basis. Because of it, our country is left with less access to cancer care in communities – particularly in rural and underserved regions – as well as unnecessarily high spending to receive it in hospitals."
"Filing this lawsuit was a last resort after numerous meetings, discussions, and letters to HHS and OMB that went nowhere. We had hoped that the current Administration would have fixed what is a constitutional violation that is clearly harming seniors with cancer," said Ted Okon, executive director of COA."Community oncologists support and want to work together with the Administration on solutions to reduce drug prices and health care spending. However, the sequester cut does not do that. It has backfired in spectacular fashion, costing seniors and Medicare billions. It is time for this madness to stop."
Independent community oncology practices and providers are dedicated to lowering the escalating cost of cancer care. They have been pioneering oncology payment reform for years, including private payer programs based on the Oncology Medical Home, the Medicare Oncology Care Model (OCM), and working on the next-generation, improved OCM 2.0 model that includes payment for cancer drugs based on value.
The Community Oncology Alliance (COA) is a non-profit organization dedicated solely to preserving and protecting access to community cancer care, where the majority of Americans with cancer are treated. COA leads community cancer clinics in navigating an increasingly challenging environment to provide efficiencies, patient advocacy, and proactive solutions to Congress and policymakers. Learn more about COA at www.CommunityOncology.org. -
Guys.. this is getting political. I understand the passion, but this should be about Research, NOT LAWSUITS..
-
While I agree that I'd strongly prefer that we not descend into bickering about the politics surrounding health-related issues, I think that a simple reference (link) to credible news sources covering issues that may affect access to cancer-related health care is fair game for posting. Factual vs. editorial material would seem more suitable. I'm betting most of us hope that reporting on research will remain the focus of posted content.
On that note....
After Years of Trying, Virginia Finally Will Expand Medicaid
https://www.nytimes.com/2018/05/30/health/medicaid...
Why Virginia's Medicaid expansion is a big deal
https://www.washingtonpost.com/news/powerpost/palo...
{editor's note: These articles do address the political environment surrounding expansion. Access at your own risk.}
-
Lumpie, I was directing my post more to the article Lilac posted about a lawsuit - which has nothing to do with Research. The Right to Try bill that you posted about is about Research and cutting edge medicine, so in my opinion it belongs. The others though... have nothing to do with research and should be on a separate thread that deals with 'Medicaid and such'.. This is a Breaking Research thread, not 'all issues related to health care" thread.
-
Lisey, understand your point, yet, as stated before, what I posted is completely health-care cancer related and I'm not deleting. Feel free to scroll.
-
About that teaser Healio blurb regarding the upcoming release of phase 3 TAILORx results--Oncotype DX scores of 11-17 are NOT "intermediate." Genomic Health's own classification specifies 0-17 as "low risk," 18-24 as "intermediate risk" and anything above that as "high risk" for recurrence. The only thing "intermediate" about the 11-17 ODX cohort is that it lies between the first group of 0-10 scoring women (per Genomic's classification, very low risk who should definitely skip chemo) for which data was released and the high-risk cohort for whom chemo is definitely beneficial. I would not use the term "intermediate" for scores of 11-17 because it connotes a risk that the test's own developer concedes doesn't exist. But if laypeople (or non-oncologist physicians) read that article, they may not realize that its term "intermediate" is unrelated to the actual risk category.
-
Lilac, this post isn't for 'all things health care related' but for RESEARCH NEWS only. Make your own thread with lawsuits and medicare and other healthcare related items from whatever sites you want, but I think this thread should JUST be about Research, which is why I have it as a favorite. I have no desire to read about politics and lawsuits due to politics.
-
Lisey, I have this thread as a favorite too.
-
There’s plenty of room for everyone. Sometimes threads evolve, wander, return... or take off in a new direction.
-
Engineered antibody summons immune system to kill cancer cells
Published TodayFact checked by Jasmin Collier
https://www.medicalnewstoday.com/articles/322007.p... -
SIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!
SPECIALTY TOPICSCURRENTLY VIEWING
Breast Cancer
All Specialties
Conference Coverage > 2018 ASCO Annual Meeting >Dr. Mohile on Using a Geriatric Assessment in Older Patients With Cancer
Supriya Gupta Mohile, MD, MSPublished: Saturday, Jun 02, 2018
Supriya Gupta Mohile, MD, MS, professor of medicine and surgery, James Wilmot Cancer Institute, director, Geriatric Oncology Clinic, University of Rochester, discusses clustered findings with a geriatric assessment for older patients with cancer in an interview with OncLive during the 2018 ASCO Annual Meeting.
A geriatric assessment is a standardized tool to assess health status in older adults, using age, comorbidity, and performance status. However, those characteristics are not the most effective way to identify patients at highest risk of poor outcomes, Mohile explains. Evidence suggest that geriatric assessments can help oncologists identify patients who are at the highest risk of adverse outcomes, such as toxicity from treatment, hospitalization, mortality, and functional decline. These have also been published in recent ASCO guidelines, she adds.
Patients aged 70 and older may have medical conditions other than cancer that would make them unlikely candidates for clinical trials, but their life expectancy is often long enough to warrant cancer treatment; however, there are limited data for these patients. Mohile questions how oncologists can improve conversations about issues that older patients and caregivers care about, and how the geriatric assessment can be used to do that.
The clustered study showed that providing a geriatric assessment summary to oncologists increases the number and quality of discussions about age-related concerns and improves patient satisfaction. -
So radiation causes increased toxicity and morbidity, interesting. But a little confusing
VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!
SPECIALTY TOPICSCURRENTLY VIEWING
Breast Cancer
All Specialties
View more on OncLive TV >>Dr. Kubicky on the Optimal Use of Radiation in Patients With Breast Cancer
Charlotte Kubicky, MD, PhDPublished: Tuesday, May 29, 2018
-
Extending Adjuvant Endocrine Therapy in Patients With ER-Positive Breast Cancer
AAARGHH!!! More bait-and-switch. The second paragraph mentions "...and more recently, aromatase inhibitors." BUT the article goes on to describe a few studies, ALL of which involved only tamoxifen. Even discussion of non-adherence to endocrine therapy specified tamoxifen intolerance in older women--not one word about AIs, which are now the gold standard for postmenopausal ER+ patients.
Still waiting to see what phase 3 of the TAILORx study will say about the appropriateness of chemo for those of us with OncotypeDX scores of 11-17. Betcha it'll still be equivocal, and not distinguish between us and the truly "intermediate-risk" (18-25) patients--but will simply lump us all together. Hope to be pleasantly surprised and helpfully informed, but fully expect to be frustrated and have to wait yet another year for accurate answers.
-
Radiotherapy offers new treatment option for liver cancer
A novel technique that delivers high doses of radiation to tumors while sparing the surrounding normal tissue shows promise as a curative treatment option for patients with early-stage liver cancer, according to a study published ...
-
Cancer researchers are now studying whether fitness trackers can be tools to measure a patient's quality of life: https://www.theguardian.com/technology/2018/jun/01/cancer-fitbit-treatment-chemotherapy
-
TAILORx Results Published Today in New England Journal of Medicine Identifies the 70% of Women with Early-stage Breast Cancer Who Receive No Benefit from Chemotherapy
“The TAILORx study definitively established that chemotherapy may be spared in about 70 percent of these patients, including all women older than 50 with Breast Recurrence Score® results of 0 to 25 and all women age 50 or younger with Breast Recurrence Score results of 0 to 15.
Importantly, 30 percent of early-stage breast cancer patients will derive benefit from chemotherapy, including women of any age with Breast Recurrence Score results of 26 to 100, and in women younger than 50, where a modest (2 percent) benefit from chemotherapy was observed with Breast Recurrence Score results of 16 to 20, which gradually grew as scores increased up to and above 25. This important finding reveals a new level of precision of chemotherapy benefit for younger patients that only the Oncotype DX® test can provide."
-
I don’t have much faith in the Oncotype DX. I scored a 6 did chemo and now stage IV.
-
Thank you Diana Rose. They wouldn’t give me the Oncotype test because I turned down chemo. So sorry you are stage IV
-
So sorry Diana Rose. That is a low score. Mine was 11. Stage 1b, grade 1 IDC. I didn’t have chemo either only radiation +Tamoxifen for 5 years. Currently 6 1/2 years out.
Diane
-
Dianarose, I am sorry. Nothing is for certain it seems. They didn't give me the test because my Grade was low, and perhaps because I am older. Not sure if is a good thing or not but I was glad not to have chemo.
-
-
Thank you April! Wonderful news. I don't find it ironic at all!
Categories
- All Categories
- 679 Advocacy and Fund-Raising
- 289 Advocacy
- 68 I've Donated to Breastcancer.org in honor of....
- Test
- 322 Walks, Runs and Fundraising Events for Breastcancer.org
- 5.6K Community Connections
- 282 Middle Age 40-60(ish) Years Old With Breast Cancer
- 53 Australians and New Zealanders Affected by Breast Cancer
- 208 Black Women or Men With Breast Cancer
- 684 Canadians Affected by Breast Cancer
- 1.5K Caring for Someone with Breast cancer
- 455 Caring for Someone with Stage IV or Mets
- 260 High Risk of Recurrence or Second Breast Cancer
- 22 International, Non-English Speakers With Breast Cancer
- 16 Latinas/Hispanics With Breast Cancer
- 189 LGBTQA+ With Breast Cancer
- 152 May Their Memory Live On
- 85 Member Matchup & Virtual Support Meetups
- 375 Members by Location
- 291 Older Than 60 Years Old With Breast Cancer
- 177 Singles With Breast Cancer
- 869 Young With Breast Cancer
- 50.4K Connecting With Others Who Have a Similar Diagnosis
- 204 Breast Cancer with Another Diagnosis or Comorbidity
- 4K DCIS (Ductal Carcinoma In Situ)
- 79 DCIS plus HER2-positive Microinvasion
- 529 Genetic Testing
- 2.2K HER2+ (Positive) Breast Cancer
- 1.5K IBC (Inflammatory Breast Cancer)
- 3.4K IDC (Invasive Ductal Carcinoma)
- 1.5K ILC (Invasive Lobular Carcinoma)
- 999 Just Diagnosed With a Recurrence or Metastasis
- 652 LCIS (Lobular Carcinoma In Situ)
- 193 Less Common Types of Breast Cancer
- 252 Male Breast Cancer
- 86 Mixed Type Breast Cancer
- 3.1K Not Diagnosed With a Recurrence or Metastases but Concerned
- 189 Palliative Therapy/Hospice Care
- 488 Second or Third Breast Cancer
- 1.2K Stage I Breast Cancer
- 313 Stage II Breast Cancer
- 3.8K Stage III Breast Cancer
- 2.5K Triple-Negative Breast Cancer
- 13.1K Day-to-Day Matters
- 132 All things COVID-19 or coronavirus
- 87 BCO Free-Cycle: Give or Trade Items Related to Breast Cancer
- 5.9K Clinical Trials, Research News, Podcasts, and Study Results
- 86 Coping with Holidays, Special Days and Anniversaries
- 828 Employment, Insurance, and Other Financial Issues
- 101 Family and Family Planning Matters
- Family Issues for Those Who Have Breast Cancer
- 26 Furry friends
- 1.8K Humor and Games
- 1.6K Mental Health: Because Cancer Doesn't Just Affect Your Breasts
- 706 Recipe Swap for Healthy Living
- 704 Recommend Your Resources
- 171 Sex & Relationship Matters
- 9 The Political Corner
- 874 Working on Your Fitness
- 4.5K Moving On & Finding Inspiration After Breast Cancer
- 394 Bonded by Breast Cancer
- 3.1K Life After Breast Cancer
- 806 Prayers and Spiritual Support
- 285 Who or What Inspires You?
- 28.7K Not Diagnosed But Concerned
- 1K Benign Breast Conditions
- 2.3K High Risk for Breast Cancer
- 18K Not Diagnosed But Worried
- 7.4K Waiting for Test Results
- 603 Site News and Announcements
- 560 Comments, Suggestions, Feature Requests
- 39 Mod Announcements, Breastcancer.org News, Blog Entries, Podcasts
- 4 Survey, Interview and Participant Requests: Need your Help!
- 61.9K Tests, Treatments & Side Effects
- 586 Alternative Medicine
- 255 Bone Health and Bone Loss
- 11.4K Breast Reconstruction
- 7.9K Chemotherapy - Before, During, and After
- 2.7K Complementary and Holistic Medicine and Treatment
- 775 Diagnosed and Waiting for Test Results
- 7.8K Hormonal Therapy - Before, During, and After
- 50 Immunotherapy - Before, During, and After
- 7.4K Just Diagnosed
- 1.4K Living Without Reconstruction After a Mastectomy
- 5.2K Lymphedema
- 3.6K Managing Side Effects of Breast Cancer and Its Treatment
- 591 Pain
- 3.9K Radiation Therapy - Before, During, and After
- 8.4K Surgery - Before, During, and After
- 109 Welcome to Breastcancer.org
- 98 Acknowledging and honoring our Community
- 11 Info & Resources for New Patients & Members From the Team